You can help elevate the standard of care for Women’s Health and STIs
Clinicians and laboratories are faced with increasing challenges in managing workload and patient needs when it comes to reproductive health. Staggering costs to the U.S. healthcare system caused by the growing number of new infections demand action in the way we test for sexually transmitted infections (STIs). For vaginal infections, traditional diagnostics leave up to 40% of women with vaginitis undiagnosed after an initial clinical visit.
Explore the BD MAX Women’s Health and STI Portfolio
The BD MAX Women’s Health and STI portfolio is focused on providing accurate, reliable results that enable clinicians and labs to elevate patient care.
BD MAX Vaginal Panel
Vulvovaginal complaints are one of the most common reasons for women to seek medical advice.
BD MAX CT/GC/TV
Testing simultaneously for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), and Trichomonas vaginalis (TV) is optimal for detection of the most common treatable STIs in female patients.
BD MAX GBS
Group B streptococcal disease (GBS) is the leading infectious cause of morbidity and mortality among infants in the United States.
- Centers for Disease Control and Prevention. http://www.cdc.gov/std/stats/sti-estimates-fact-sheet-feb-2013.pdf. Accessed September 19, 2016.
- Carr PL et al. “Shotgun” versus sequential testing. Cost-effectiveness of diagnostic strategies for vaginitis. JGIM. 2005;793-799.
- Hainer BL, Gibson MV. Vaginitis. Am Fam Physician. 2011;83(7):807-815.
- Baron EJ et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clin Infect Dis. 2013;57(4):e22-e121.
- Verani JR, McGee L, Schrag G; Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease: revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010;59(RR-10):1-32.